OS Therapies (OSTX) Competitors $1.84 -0.05 (-2.65%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock OSTX vs. CYBN, FDMT, SLN, TLSA, INMB, ACIU, PBYI, NLTX, SLS, and ALTSShould you be buying OS Therapies stock or one of its competitors? The main competitors of OS Therapies include Cybin (CYBN), 4D Molecular Therapeutics (FDMT), Silence Therapeutics (SLN), Tiziana Life Sciences (TLSA), INmune Bio (INMB), AC Immune (ACIU), Puma Biotechnology (PBYI), Neoleukin Therapeutics (NLTX), SELLAS Life Sciences Group (SLS), and Janone (ALTS). These companies are all part of the "pharmaceutical products" industry. OS Therapies vs. Its Competitors Cybin 4D Molecular Therapeutics Silence Therapeutics Tiziana Life Sciences INmune Bio AC Immune Puma Biotechnology Neoleukin Therapeutics SELLAS Life Sciences Group Janone Cybin (NYSE:CYBN) and OS Therapies (NYSE:OSTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, community ranking, dividends and media sentiment. Which has higher earnings & valuation, CYBN or OSTX? OS Therapies is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$57.88M-$4.38-1.97OS TherapiesN/AN/A-$7.79M-$0.86-2.14 Does the MarketBeat Community believe in CYBN or OSTX? Cybin received 4 more outperform votes than OS Therapies when rated by MarketBeat users. CompanyUnderperformOutperformCybinOutperform Votes17100.00% Underperform VotesNo VotesOS TherapiesOutperform Votes13100.00% Underperform VotesNo Votes Do analysts prefer CYBN or OSTX? Cybin presently has a consensus price target of $86.00, suggesting a potential upside of 894.22%. OS Therapies has a consensus price target of $18.00, suggesting a potential upside of 878.26%. Given Cybin's higher possible upside, equities analysts plainly believe Cybin is more favorable than OS Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25OS Therapies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 Does the media favor CYBN or OSTX? In the previous week, Cybin had 4 more articles in the media than OS Therapies. MarketBeat recorded 7 mentions for Cybin and 3 mentions for OS Therapies. Cybin's average media sentiment score of 0.78 beat OS Therapies' score of 0.00 indicating that Cybin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OS Therapies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in CYBN or OSTX? 17.9% of Cybin shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 13.8% of OS Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is CYBN or OSTX more profitable? OS Therapies' return on equity of 0.00% beat Cybin's return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -37.58% -36.59% OS Therapies N/A N/A -569.57% SummaryCybin beats OS Therapies on 8 of the 13 factors compared between the two stocks. Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OSTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OSTX vs. The Competition Export to ExcelMetricOS TherapiesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$51.70M$6.92B$5.61B$19.87BDividend YieldN/A2.55%5.28%3.83%P/E Ratio-2.148.6727.1735.60Price / SalesN/A262.53410.9643.81Price / CashN/A65.8538.2517.51Price / BookN/A6.597.064.85Net Income-$7.79M$143.75M$3.23B$1.02B7 Day Performance10.18%0.82%0.77%0.90%1 Month Performance1.66%12.09%9.67%2.35%1 Year PerformanceN/A4.46%32.02%10.79% OS Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OSTXOS Therapies1.8912 of 5 stars$1.84-2.6%$18.00+878.3%N/A$51.70MN/A-2.14N/ACYBNCybin3.0243 of 5 stars$8.10+1.8%$86.00+961.7%N/A$173.96MN/A-1.8550News CoverageAnalyst RevisionFDMT4D Molecular Therapeutics2.9327 of 5 stars$3.75+3.6%$29.56+688.1%-81.3%$173.72M$23K-1.32120Analyst ForecastAnalyst RevisionSLNSilence Therapeutics3.0962 of 5 stars$5.73-1.9%$33.83+490.5%-73.1%$171.50M$27.70M-3.65100Positive NewsTLSATiziana Life Sciences1.223 of 5 stars$1.44+5.9%N/A+74.0%$168.26MN/A0.008Gap UpINMBINmune Bio2.0955 of 5 stars$7.19-2.6%$22.80+217.1%-9.5%$165.26M$50K-3.3010News CoveragePositive NewsGap UpACIUAC Immune3.0165 of 5 stars$1.65-3.8%$12.00+629.5%-55.4%$165.17M$28.30M-3.58140Positive NewsPBYIPuma Biotechnology4.1417 of 5 stars$3.29+0.3%$7.00+112.8%-1.0%$163.29M$232.71M6.85200Positive NewsNLTXNeoleukin TherapeuticsN/A$17.01-9.2%N/A-43.7%$159.86MN/A-5.4790High Trading VolumeSLSSELLAS Life Sciences Group0.3151 of 5 stars$1.58-7.6%N/A+13.8%$157.65M$1M-2.2910Short Interest ↑High Trading VolumeALTSJanoneN/A$9.01-3.2%N/AN/A$157.27M$18.05M0.00170Short Interest ↑Gap Down Related Companies and Tools Related Companies Cybin Competitors 4D Molecular Therapeutics Competitors Silence Therapeutics Competitors Tiziana Life Sciences Competitors INmune Bio Competitors AC Immune Competitors Puma Biotechnology Competitors Neoleukin Therapeutics Competitors SELLAS Life Sciences Group Competitors Janone Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OSTX) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OSTX Stock Free OSTX Stock Alerts